23/01/2026
UCLH has recruited the first participant to a new study testing an investigational combination of therapies in patients with advanced lung cancer.
The global study, known as BNT324-01 and sponsored by BioNTech SE, is testing the investigational drugs BNT324 and BNT327 in patients with advanced lung cancer. BNT324, is a ‘targeted chemotherapy’ designed to target a protein called B7-H3, which is found in large amounts in many cancer cells and deliver the chemotherapy directly to the cancer. The other drug, BNT327, is a form of immunotherapy, designed to block particular proteins which play a role in immune control and the formation of blood vessels that can feed cancer cells.
UCLH medical oncologist Martin Forster (pictured), who is the UK Chief Investigator on the trial, said: “Despite recent improvements in treatment, the proportion of patients with advanced lung disease living beyond two years in still far too low and we are in desperate need of new drugs to improve outcomes for our patients. Both of these investigational drugs are very innovative, and we hope they can be safely given together. As they work against the cancer in different ways, we hope they will complement each other and have a much bigger anti-cancer effect when combined.”
Find out more: https://www.uclh.nhs.uk/news/new-combination-therapy-trial-lung-cancer-open-recruitment